{"groups":[{"description":"Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day","id":"FG000","title":"Cohort I"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"psychiatric instability"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"76"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"68"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Between November 2001 and February 2007 sixty eight patients were treated on this protocol and have been included in the analysis"}